Review
Jul 2026
Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemia.
Overall, both olezarsen and plozasiran appear generally well tolerated, although monitoring of liver enzymes and glycemic control is warranted for both agents, and additional monitoring of platelet counts for olezarsen.
Michael S Kelly, Jelena Lewis, Dylan Zuch et al.
· Journal of Cardiovascular Ph... · 0 citations